Smith & Nephew hit with FDA warning letter

Smith & Nephew has received an FDA warning letter over quality control concerns arising from a July inspection of the company's Tuttlingen, Germany facility. The devicemaker had sent a response to the agency in August concerning the observations seen at the facility, which makes hip implants, but the FDA deemed it inadequate.

In the Dec. 21 letter, the FDA maintains that required tests were not performed and the company had failed to establish and maintain procedures to correct problems in the manufacture of the R3 ceramic acetabular system, a hip replacement device. The letter highlights one instance in which the company implemented new packaging procedures and retrained employees following problems with irradiation. In spite of the company's actions, problems continued. "The firm's management stated that the recurring nonconformities may be attributed to employees not following directions," the letter states.

The devicemaker said it had not yet seen the contents of the letter but  had taken remedial action to solve issues raised by the FDA . "The device is also made in Warwick, UK, and Memphis so there is no problem in supply," a company spokesman said. He added there had been no reports of patient incidents, Reuters notes.

Bloomberg reports that Smith & Nephew fell the most in six months in London trading after the letter was revealed.

- read the warning letter
- get more from Bloomberg
-
check out the Reuters story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.